Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus Cabozantinib in Advanced Urothelial Cancer
NCT03425201Phase 2Completed
- Sponsor
- Fundación CRIS contra el Cáncer
- Start
- Oct 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, cabozantinib in urothelial carcinoma (UC), renal cell carcinoma (RCC), sponsored by Fundación CRIS contra el Cáncer. Started Oct 2019; status: completed.
02
Drugs
niraparibcabozantinib
03
Conditions
urothelial carcinoma (UC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03425201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425201.